While blood-based tests are readily available for various conditions, including
cardiovascular diseases, type 2 diabetes, and common cancers, Alzheimer's disease (AD) …

Objective A clock relating amyloid positron emission tomography (PET) to time was used to
estimate the timing of biomarker changes in sporadic Alzheimer disease (AD). Methods …

PURPOSE By 2040, 21.6% of Americans will be over age 65, and the population of those
older than age 85 is estimated to reach 14.4 million. Although not causative, older age is a …

Blood-based biomarkers of Alzheimer disease (AD) may facilitate testing of historically
under-represented groups. The Study of Race to Understand Alzheimer Biomarkers …

INTRODUCTION Blood tests have the potential to improve the accuracy of Alzheimer's
disease (AD) clinical diagnosis, which will enable greater access to AD‐specific treatments …

INTRODUCTION In the research setting, obtaining accurate established biomarker
measurements and maximizing use of the precious samples is key. Accurate technologies …

Alzheimer's disease biomarkers are crucial to understanding disease pathophysiology,
aiding accurate diagnosis and identifying target treatments. Although the number of …

INTRODUCTION Blood‐based biomarkers are a cost‐effective and minimally invasive
method for diagnosing the early and preclinical stages of amyloid positivity (AP). Our study …

Epidemiological evidence suggests the presence of common risk factors for the
development and prognosis of both cardio-and cerebrovascular diseases, including stroke …

BACKGROUND This study investigated the potential of phosphorylated plasma Tau217 ratio
(pTau217R) and plasma amyloid beta (Aβ) 42/Aβ40 in predicting brain amyloid levels …